How to tell whether a PRP result matters to you

Check the body part and time watched

Find which body part and cause the research covered. A knee arthritis result won't answer a torn tendon question. How worn the joint looked can also change the match.

Then see how long people were watched after treatment. Relief after several weeks may not last for months. Use the time that matters in your own life.

See what the other people received

Good research compares PRP with dummy care. Other people may get salt water in the joint. For a tendon, a needle may stop before reaching the sore tissue.

Both groups might also follow the same exercise plan. If they improve together, PRP may not have added much. That's the plain answer worth finding.

Take one useful question to the visit

Ask whether enough people improved to notice at home. The answer needs the same body part and follow-up time. It can't borrow a knee result for a shoulder.

Take the research with you if a claim caught your eye. Ask the provider how your exam compares with the people studied. Orthobiologics are non-surgical treatments made from your blood or other body tissue; PRP uses its platelet-rich portion. QC Kinetix can discuss these choices with you at its Peoria clinic, where medical providers prepare the care.

Sources

1. A meta-analysis of 73 articles covering 5,895 patients quantified the PLACEBO response to intra-articular injection in knee osteoarthritis: statistically and clinically significant improvements in pain, function and quality of life at 1, 3 and 6 months, with responder rates above 50% at each of those points, declining by 12 months. The placebo response was stronger in trials with more female participants and in more recently published trials. This is why an uncontrolled 'our patients improved' figure carries almost no information.

   Previtali D, Boffa A, Di Laura Frattura G, et al. — Placebo response to intra-articular injections in knee osteoarthritis: magnitude, evolution over time, and influencing factors. A systematic review and meta-analysis with meta-regression. EFORT Open Reviews, 2025. DOI: 10.1530/EOR-2025-0022.

2. A Bayesian network meta-analysis restricted to LARGE randomized trials (at least 100 patients per group; 57 trials, 22,795 participants, 18 intra-articular interventions) found treatment effects were larger in the 35 high-risk-of-bias trials than in the 22 low/unclear-risk trials. Excluding high-risk trials, the effects of 16 of the 18 intra-articular interventions in knee or hip OA were smaller than the minimal clinically important difference and most were consistent with placebo effects; triamcinolone had the highest probability of exceeding the MID at weeks 2-6.

   Pereira TV, Saadat P, Bobos P, et al. — Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis based on large randomized trials: A systematic review and network meta-analysis. Osteoarthritis and Cartilage, 2025. DOI: 10.1016/j.joca.2024.08.014.

3. A Delphi consensus of 24 invited experts produced the Minimum Information for Studies Evaluating Biologics in Orthopaedics (MIBO) checklists: 58 items reached consensus for PRP and were compiled into a 23-statement reporting checklist, with a parallel 25-statement checklist for mesenchymal stem cells. The need for it was identified because clinical studies of PRP and MSCs are 'limited by inadequate reporting of scientific details critical to outcome'.

   Murray IR, Geeslin AG, Goudie EB, et al. — Minimum Information for Studies Evaluating Biologics in Orthopaedics (MIBO): Platelet-Rich Plasma and Mesenchymal Stem Cells. Journal of Bone and Joint Surgery (American), 2017. DOI: 10.2106/JBJS.16.00793.

4. A systematic review of 105 clinical PRP studies in orthopaedics published 2006-2016 found that only 11 (10%) described the preparation protocol clearly enough for another investigator to repeat it, and only 17 (16%) reported any quantitative metric of the final PRP composition. The authors concluded that the current reporting of PRP preparation and composition does not allow the PRP products actually delivered to patients to be compared between studies.

   Chahla J, Cinque ME, Piuzzi NS, et al. — A Call for Standardization in Platelet-Rich Plasma Preparation Protocols and Composition Reporting: A Systematic Review of the Clinical Orthopaedic Literature. Journal of Bone and Joint Surgery (American), 2017. DOI: 10.2106/JBJS.16.01374.

5. A meta-analysis of 34 randomized trials (1403 PRP knees, 1426 control knees) found WOMAC favoured PRP over placebo at 12 months (P=.02) and over hyaluronic acid at 6 and 12 months (P<.001), and favoured PRP over steroids on VAS pain and KOOS at 6 months. Critically, the authors reported that the superiority of PRP did NOT reach the minimal clinically important difference for any outcome, and graded the quality of evidence as low.

   Filardo G, Previtali D, Napoli F, et al. — PRP Injections for the Treatment of Knee Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials. Cartilage, 2021. DOI: 10.1177/1947603520931170.

6. The devices used to spin PRP at the point of care are cleared by FDA as clinical centrifuges, product code JQC, a Class I device under 21 CFR 862.2050 - for example the Biomet GPS Platelet Separation Kit (K030555, cleared 2003) and the Harvest SmartPrep2 / SmartPrep Platelet Concentration System (K103340, cleared 2010). That clearance covers the equipment that separates blood. It is not an FDA approval of platelet-rich plasma as a treatment for osteoarthritis, tendinopathy or any other orthopedic condition, and copy must never blur the two.

   U.S. Food and Drug Administration (Center for Devices and Radiological Health) — 510(k) Premarket Notification database and Product Classification: JQC, Centrifuges (Micro, Ultra, Refrigerated) For Clinical Use, 21 CFR 862.2050. FDA accessdata (CDRH device databases), 2003.